ArticleCancer discovery2026

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.